Proposals of Terveystalo’s Board of Directors to the Annual General Meeting 2026

Terveystalo’s Board proposes a materially higher 2025 dividend of EUR 0.64 per share (up from EUR 0.48), equivalent to ~EUR 81.1m with current share count, to be paid in two instalments (record dates 26 Mar 2026 / 8 Oct 2026; payment dates 8 Apr 2026 / 15 Oct 2026). The Board also proposes adoption of the 2025 financials (parent company distributable funds EUR 582.1m; 2025 result EUR 83.9m), election of KPMG as auditor and sustainability assurance provider, amendments to the Articles to allow flexible auditor terms, and authorizations for repurchasing and issuing up to 12,703,653 shares (~10%) plus a EUR 150k charitable donation cap — measures that are shareholder‑friendly and may support the equity. The AGM is scheduled for 24 March 2026.

Analysis

Market structure: The board’s EUR 0.64/share dividend (≈EUR81.1m) plus a 10% share buyback authorization directly benefits equity holders and should support TTALO’s near-term equity valuation and credit metrics; conversely, competitors with weaker cash generation face pressure on pricing and customer retention as Terveystalo can afford customer-facing investments. The dual authorizations (repurchase and up-to-10% issuance) keep strategic flexibility—signal is cash-rich but not committed to M&A; the dividend equals ~97% of 2025 reported profit (83.9m), implying a near-term cash-return focus rather than reinvestment.

Risk assessment: Tail risks include a regulatory hit to Finnish/Swedish reimbursement (negative shock >10% revenue), adverse outcomes from Swedish occupational-health exposure, or large directed share issuance/dilution that offsets buybacks. Immediate risks (days): AGM vote and ex-div timing (record 26 Mar); short-term (weeks/months): market reaction to dividend capture and any buyback execution; long-term (quarters/years): margin pressure from wage inflation or contract renewals. Hidden dependencies: concentration in corporate contracts and reliance on digital appointment volumes (2.7m app users) that can decline with macro slowdown.

Trade implications: Favor a tactical long on Terveystalo (TTALO, Nasdaq Helsinki) sized 2–3% NAV ahead of AGM if market hasn’t priced dividend; implement covered-call overlays around ex-div dates to monetize yield and sell-pair protection (put spreads 5–8% OTM) rather than naked exposure. Cross-asset: positive for senior credit spreads (tighten), may compress option IV; small EUR appreciation possible from improved Finnish corporate cash flows.

Contrarian angles: Consensus may treat this as risk-free yield; missing is diminished organic reinvestment and the conditional 10% issuance that could be used for M&A/dilution—if management pivots to buy growth with shares, equity upside will be muted. Historical parallels: Nordic service providers that paid high dividends then issued equity for bolt-on M&A saw share underperformance; watch for directed repurchases (could benefit insiders) and demand softness that would make the high payout unsustainable.

Key Decisions for Investors

• Establish a 2–3% NAV long position in Terveystalo (TTALO, Nasdaq Helsinki) within 7 trading days pre-AGM if the share price has not already priced the EUR0.64 dividend; set a 6–9 month target total return of 10–15% and a stop-loss at -8% from entry.
• Implement a covered-call income leg: buy 1–2% position in TTALO and sell 3-month OTM calls ~5–8% above entry to capture option premium plus dividend; roll after ex-dividend dates (8 Apr and 15 Oct) unless buyback announcements justify retaining shares.
• Use a cash-secured short-put spread if you prefer limited downside: sell a 30–90 day put ~5% OTM and buy a deeper put ~10% OTM on TTALO for a net credit; target ≥2–3% monthly yield on capital at risk and close if spread moves to 50% of max loss.
• Hedge regulatory/sector risk by reducing 1–2% exposure to Nordic healthcare services and redeploy to global defensive healthcare (e.g., XLV) or investment-grade Nordic corporates until clarity from AGM (24 Mar) and any buyback execution announced by 30 Jun 2026.
• Trigger-based scale: if the Board announces directed buybacks using >50% of authorized volume within 90 days post-AGM, increase long TTALO position by an incremental 2–3%; conversely, if management issues equity >5% within 6 months, reduce exposure by 50%.